ArticleEuropean archives of psychiatry and clinical neuroscience2026
Genetic predisposition to unwanted side effects under antidepressants and antipsychotics: a molecular-genetic study of 902 patients over 6 weeks.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This project aimed at (1) detailing the complex side effect patterns of 902 inpatients treated for major depression or schizophrenia under polypharmacy regimens; (2) developing a quantitative side effect model that accounts for the various facets of clinically observable adverse events; and (3) analyzing irregularities in genetic diversity through multidimensional "gene vectors" in order to reveal possible interrelations with side effect clusters. The patients' acute medication, their time course of recovery, and their side effects were assessed by up to 8 repeated measurements. The genotyping included 100 candidate genes with genotypic patterns computed from 549 Single Nucleotide Polymorphisms (SNPs). Between 61.9% and 68.1% of study patients reported moderate to severe side effects, while response rates were with 29.5-35.7% quite modest. Half of the patients (52.1%) experienced weight gains of ≥ 2 kg. On the phenotype level, up to 30% of the observed variance could be "explained" by regression models with the dominating factor "number of concurrent drugs". On the genotype level, we relied on standard Artificial Intelligence (AI) procedures along with multilayer Neural Nets (NNs) to search for combinations of multidimensional genotypic patterns that were characteristic of patients with severe side effects, while being rare (< 10%) among patients without side effects. These analyses failed to explain a clinically relevant proportion of the observed phenotypic variance. The 14 cytochromes analyzed were found to play no more than a minor role. While type and severity of side effects under polypharmacy were primarily determined by the overall medication "load", the actually observed side effect patterns varied considerably between patients receiving the same medication "load", thus stressing the role of genetics. Our results suggested that the role of genetics in the development of severe side effects under polypharmacy is by far more complex than previously assumed, related to a completely different set of genes, or that there exists genotypic heterogeneity such that multiple pathways on the genotype level lead to the same clinical picture on the phenotype level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.